About Scala Biodesign
Scala Biodesign is a company based in Tel Aviv (Israel) founded in 2021 by Adi Goldenzweig and Ravit Netzer. Scala Biodesign has raised $21.5 million across 2 funding rounds from investors including TLV Partners, Grove Ventures and Deep Insight. Scala Biodesign offers products and services including Protein Stability Platform, Enzyme Optimization Platform, and Antibody Humanization Platform. Scala Biodesign operates in a competitive market with competitors including Liberation Labs, NJ Bio, Shantani Proteome Analytics, Kinaxo Biotechnologies and Peplib, among others.
- Headquarter Tel Aviv, Israel
- Founders Adi Goldenzweig, Ravit Netzer
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$21.5 M (USD)
in 2 rounds
-
Latest Funding Round
$16 M (USD), Series A
Mar 31, 2026
-
Investors
TLV Partners
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Scala Biodesign
Scala Biodesign offers a comprehensive portfolio of products and services, including Protein Stability Platform, Enzyme Optimization Platform, and Antibody Humanization Platform.
Improves protein stability for therapeutic and industrial use
Enhances enzyme activity and specificity for manufacturing
Optimizes antibodies for stability and therapeutic applications
People of Scala Biodesign
Unlock access to complete
Funding Insights of Scala Biodesign
Scala Biodesign has successfully raised a total of $21.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $16 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scala Biodesign
Scala Biodesign has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include TLV Partners, Grove Ventures and Deep Insight.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm investing in early stage startups in Israel & the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Scala Biodesign
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scala Biodesign
Investment portfolio details for Scala Biodesign
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Scala Biodesign
Detailed financials for Scala Biodesign
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scala Biodesign Comparisons
Peer comparison for Scala Biodesign
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scala Biodesign
Scala Biodesign operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Liberation Labs, NJ Bio, Shantani Proteome Analytics, Kinaxo Biotechnologies and Peplib, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Fermentation products are manufactured and commercialized via CRO services.
|
|
| Locked | Locked | Locked |
Clinical development services are provided for biotechnology applications.
|
|
| Locked | Locked | Locked |
Drug discovery services are delivered via chemical-proteomics technologies.
|
|
| Locked | Locked | Locked |
Chemical proteomics for cellular target profiling and drug discovery services
|
|
| Locked | Locked | Locked |
Provider of peptide drug discovery and development services for global pharmaceutical industries
|
Detailed competitors of Scala Biodesign
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scala Biodesign
Complete news archive for Scala Biodesign
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scala Biodesign
Scala Biodesign was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Scala Biodesign is headquartered in Tel Aviv, Israel.
Ravit Netzer is the current CEO of Scala Biodesign. They have also founded this company.
Scala Biodesign is a funded company, having raised a total of $21.5M across 2 funding rounds to date.
Scala Biodesign was founded in 2021 in Tel Aviv, Israel, focusing on the biotechnology sector. Computational methods are utilized to create protein designs, with one-shot approaches employed to streamline processes and enhance efficiency. Services target acceleration of protein engineering for various applications, supported by a team including co-founders Adi Goldenzweig and Ravit Netzer as CEO. Operations emphasize scalable solutions for research and development needs.
Scala Biodesign's top competitors include Liberation Labs, NJ Bio and Shantani Proteome Analytics.
Scala Biodesign offers Protein Stability Platform, Enzyme Optimization Platform, and Antibody Humanization Platform.
Scala Biodesign has 4 investors. Key investors include TLV Partners, Grove Ventures, Deep Insight, and Innovation Israel.